Agenus Reports Durable BOT+BAL Activity in MSS Colorectal Cancer
Lexington, Mass. – August 28, 2026 Agenus Inc. announced the publication of mature Phase 1b results evaluating botensilimab (BOT)...
PD-L1
Advertisement
Leads Biolabs Advances Opamtistomig Phase II ESCC Study
NANJING, China — August 25, 2026 Leads Biolabs announced that its proprietary Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, has...
Leads Biolabs Advances LBL-024 Data in First-Line NSCLC
NANJING, China, August 20, 2026 Leads Biolabs announced that the full abstract for its Phase II study of LBL-024...
AstraZeneca Discontinues eVOLVE-Lung02 Phase 3 Trial
Cambridge, UK — August 17, 2026 AstraZeneca announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig...
Leads Biolabs Advances Opamtistomig Phase II Trial in First-Line Liver Cancer
NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...
Advertisements
enVVeno Medical Advances FDA Pivotal Trial for enVVe System
IRVINE, Calif., July 31, 2026 enVVeno Medical Corporation reported its second quarter 2026 financial results, highlighting significant progress toward...
Leads Biolabs Completes Opamtistomig Phase II Enrollment in BTC
NANJING, China, July 30, 2026 Leads Biolabs announced that its Phase II clinical trial evaluating Opamtistomig (LBL-024), a proprietary...
City of Hope Launches Phase 2 Lung Cancer Biomarker Trial
LOS ANGELES, July 21, 2026 City of Hope has launched the national Phase 2 IMMUNO-BIOMAP clinical trial to better...
Leads Biolabs Secures Six ESMO 2026 Research Presentations
NANJING, China, July 13, 2026 Leads Biolabs has strengthened its position in global cancer immunotherapy after announcing that six...
Immutep Reports Positive INSIGHT-003 Survival Data
SYDNEY, Australia, July 13, 2026 Immutep announced positive mature overall survival data from its investigator-initiated Phase 1 INSIGHT-003 trial...
Advertisement
